Findings

What do systematic reviews say?

4,734 questions · 15,288 findings · 893 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,864 · 25.3%GRADE not reported 2,222 · 14.5%Very low 3,868 · 25.3%Low 3,280 · 21.5%Moderate 1,676 · 11%High 378 · 2.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings 2: Immunotherapies vs placebo

(2169) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 4007 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(621) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

2 findings from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1336 participants
Very low
Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1336 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(5032) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
15 studies · 4752 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(1003) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 533 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(242) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 182 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(2693) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
16 studies · 3886 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(2601) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 3615 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(4984) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 4688 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(513) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 369 participants
Very low

Summary of findings 2: Immunotherapies vs placebo

(939) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 2674 participants
Low

Summary of findings 2: Immunotherapies vs placebo

(2384) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

1 finding from 1 review

Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
17 studies · 3692 participants
Low

Summary of findings table ‐ Mental Health First Aid (MHFA) training vs alternative mental health literacy interventions

Individual mental health ‐ not measured · improving mental health and wellbeing

The review found no eligible studies for this question.

1 finding from 1 review

Mental Health First Aid as a tool for improving mental health and well‐being 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Mental Health First Aid (MHFA) training vs alternative mental health literacy interventions

Mental health service usage ‐ not measured · improving mental health and wellbeing

The review found no eligible studies for this question.

1 finding from 1 review

Mental Health First Aid as a tool for improving mental health and well‐being 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Mental Health First Aid (MHFA) training vs alternative mental health literacy interventions

Adverse effects of MHFA ‐ not measured · improving mental health and wellbeing

The review found no eligible studies for this question.

1 finding from 1 review

Mental Health First Aid as a tool for improving mental health and well‐being 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Total studies: 17 RCTs Total participants: 22,819 · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
17 studies · 22819 participants
GRADE not reported

Intervention not reported

LD‐ICS/LABA (Direct evidence; 0 RCTs; 0 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
Low

Intervention not reported

MD‐ICS/LAMA (Direct evidence; 2 RCTs; 679 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 679 participants
Low

Intervention not reported

MD‐ICS/LABA (Direct evidence; 12 RCTs; 7569 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 7569 participants
Moderate

Intervention not reported

HD‐ICS/LABA (Direct evidence; 2 RCTs; 1759 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1759 participants
Moderate

Intervention not reported

MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

The review found no eligible studies for this question.

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found